Insmed (LTS:0JAV) Marketable Securities : $796.2 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Insmed Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Insmed's Marketable Securities for the quarter that ended in Mar. 2025 was $796.2 Mil.

Insmed's annual Marketable Securities increased from Dec. 2022 ($74.2 Mil) to Dec. 2023 ($298.1 Mil) and increased from Dec. 2023 ($298.1 Mil) to Dec. 2024 ($878.8 Mil).

Insmed Marketable Securities Historical Data

The historical data trend for Insmed's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Marketable Securities Chart

Insmed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

74.24

298.07

878.80

Insmed Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															-	-	1,006.46	878.80	796.20

Insmed Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Insmed (LTS:0JAV) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Insmed Marketable Securities Related Terms

Thank you for viewing the detailed overview of Insmed's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (LTS:0JAV) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

INSM:USA IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines